Literature DB >> 9266706

Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth.

D Lacroix1, M Sonnier, A Moncion, G Cheron, T Cresteil.   

Abstract

CYP3A isoforms are responsible for the biotransformation of a wide variety of exogenous chemicals and endogenous steroids in human tissues. Two members of the CYP3A subfamily display developmentally regulated expression in the liver; CYP3A7 is expressed in the fetal liver, whereas CYP3A4 is the major cyrochrome P-450 isoform present in the adult liver. To gain insight into the descriptive ontogenesis of CYP3A isoforms during the neonatal period, we have developed several approaches to explore a neonatal liver bank. Although CYP3A4 and CYP3A7 are structurally closely related, they differ in their capacity to carry out monooxygenase reactions. We have cloned CYP3A4 and CYP3A7 and established stable transfectants in Ad293 cells to investigate their substrate specificities. The 16alpha hydroxylation of dehydroepiandrosterone is catalyzed by both proteins, but CYP3A7 has a higher affinity and maximal velocity than CYP3A4. Conversely, the conversion of testosterone into its 6beta derivative is essentially supported by CYP3A4. We used these two probes to determine the ontogenic evolution at the protein level; CYP3A7 was very active in the fetal liver and its activity was maximal during the first week following birth before to progressively decline and reached a very low level in adult livers. Conversely, the activity of CYP3A4 was extremely weak in the fetus and began to raise after birth to reach 30-40% of the adult activity after one month. CYP3A4 RNA accumulation displays a similar pattern of evolution; when probed with an oligonucleotide, its concentration increased rapidly after birth to reach a plateau as soon as the first week of age. These data supports the assumption that CYP3A4 expression is transcriptionally activated during the first week after birth and is accompanied by a simultaneous decrease of CYP3A7 expression, in such a way that the overall CYP3A protein content and the level of pentoxyresorufin dealkylase catalyzed by the two proteins remain nearly constant.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266706     DOI: 10.1111/j.1432-1033.1997.00625.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  117 in total

1.  A comparison of the pharmacokinetics of two dosing regimens of cisapride and their effects on corrected QT interval in premature infants.

Authors:  Filip Cools; Avram Benatar; Els Bruneel; Claire Theyskens; Adel Bougatef; Ann Casteels; Yvan Vandenplas
Journal:  Eur J Clin Pharmacol       Date:  2003-04-01       Impact factor: 2.953

2.  A Case Study Evaluating the Efficacy of an Ad Hoc Hospital Collection Device for Fentanyl in Infant Oral Fluid.

Authors:  Ashley M Gesseck; Justin L Poklis; Carl E Wolf; Jie Xu; Aamir Bashir; Karen D Hendricks-Muñoz; Michelle R Peace
Journal:  J Anal Toxicol       Date:  2020-10-12       Impact factor: 3.367

Review 3.  Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism.

Authors:  Timothy S Tracy; Amarjit S Chaudhry; Bhagwat Prasad; Kenneth E Thummel; Erin G Schuetz; Xiao-Bo Zhong; Yun-Chen Tien; Hyunyoung Jeong; Xian Pan; Laura M Shireman; Jessica Tay-Sontheimer; Yvonne S Lin
Journal:  Drug Metab Dispos       Date:  2015-12-17       Impact factor: 3.922

Review 4.  Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

Authors:  Christine E Staatz; Lucy K Goodman; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

Review 5.  Drugs pharmacokinetics during veno-venous extracorporeal membrane oxygenation in pediatrics.

Authors:  Matteo Di Nardo; Enno Diederick Wildschut
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

6.  Different pharmacokinetics of tramadol in mothers treated for labour pain and in their neonates. Towards an increased knowledge of paediatric clinical pharmacology.

Authors:  Trevor N Johnson
Journal:  Eur J Clin Pharmacol       Date:  2005-10-26       Impact factor: 2.953

Review 7.  Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy.

Authors:  Magnus Ingelman-Sundberg; Cristina Rodriguez-Antona
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

Review 8.  Safety of sildenafil in infants*.

Authors:  Samira Samiee-Zafarghandy; P Brian Smith; Johannes N van den Anker
Journal:  Pediatr Crit Care Med       Date:  2014-05       Impact factor: 3.624

Review 9.  Developmental pharmacokinetics in pediatric populations.

Authors:  Hong Lu; Sara Rosenbaum
Journal:  J Pediatr Pharmacol Ther       Date:  2014 Oct-Dec

Review 10.  Considerations in the pharmacologic treatment and prevention of neonatal sepsis.

Authors:  Chris Stockmann; Michael G Spigarelli; Sarah C Campbell; Jonathan E Constance; Joshua D Courter; Emily A Thorell; Jared Olson; Catherine M T Sherwin
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.